Reading view
SciEvalKit: An Open-source Evaluation Toolkit for Scientific General Intelligence
Why AI Safety Requires Uncertainty, Incomplete Preferences, and Non-Archimedean Utilities
Interpretable Link Prediction in AI-Driven Cancer Research: Uncovering Co-Authorship Patterns
Fairness Evaluation of Risk Estimation Models for Lung Cancer Screening
Harnessing Large Language Models for Biomedical Named Entity Recognition
Heterogeneity in Multi-Agent Reinforcement Learning
Multi-agent Self-triage System with Medical Flowcharts
Taming Data Challenges in ML-based Security Tasks: Lessons from Integrating Generative AI
Digital Health Technologies Applied in Patients With Early Cognitive Change: Scoping Review
Modeling hepatocellular carcinoma and its microenvironment on a chip
Cell Death Discovery, Published online: 29 December 2025; doi:10.1038/s41420-025-02917-8
Modeling hepatocellular carcinoma and its microenvironment on a chipComputational network models for forecasting and control of mental health trajectories in digital applications
npj Digital Medicine, Published online: 30 December 2025; doi:10.1038/s41746-025-02252-3
Computational network models for forecasting and control of mental health trajectories in digital applicationsMetabolic signatures in gastroenteropancreatic neuroendocrine neoplasms: unraveling diagnostic and prognostic insights
Front Endocrinol (Lausanne). 2025 Dec 11;16:1676021. doi: 10.3389/fendo.2025.1676021. eCollection 2025.
ABSTRACT
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are a heterogeneous group of tumors characterized by diverse biological behaviors and variable clinical outcomes. Recent advances have highlighted the important role of metabolic reprogramming in tumorigenesis, progression, and therapeutic resistance in GEP-NENs. In this review, we synthesize the current evidence on metabolic biomarkers and altered metabolic pathways-particularly those involving glucose, lipid, and amino acid metabolism. Key biomarkers such as GLUT-1, FASN, and enzymes involved in ferroptosis, cholesterol biosynthesis, and amino acid catabolism demonstrate strong associations with tumor aggressiveness, hypoxia, and mTOR signaling. Moreover, metabolomic profiling and functional studies suggest that metabolic markers may inform prognosis and predict response to targeted therapies such as Everolimus. Although promising, the clinical translation of these markers is still limited and requires further validation in large, subtype-specific cohorts. Our findings highlight the importance of integrating metabolic profiling into the diagnostic and therapeutic landscape of GEP-NENs. Future research should prioritize biomarker standardization, multi-omics integration, and the development of metabolism-based therapeutic strategies tailored to tumor subtype and differentiation grade.
PMID:41458541 | PMC:PMC12738315 | DOI:10.3389/fendo.2025.1676021
The global macroeconomic burden of diabetes mellitus
Nature Medicine, Published online: 29 December 2025; doi:10.1038/s41591-025-04027-5
An analysis of 204 countries estimates that diabetes will cost the global economy $10.2 trillion between the years 2020 and 2050.Evaluating Peer Online Forums to Support Health: Ethical and Practical Challenges
Context matching is not reasoning when performing generalized clinical evaluation of generative language models
npj Digital Medicine, Published online: 27 December 2025; doi:10.1038/s41746-025-02253-2
Context matching is not reasoning when performing generalized clinical evaluation of generative language modelsA novel evaluation benchmark for medical LLMs illuminating safety and effectiveness in clinical domains
npj Digital Medicine, Published online: 26 December 2025; doi:10.1038/s41746-025-02277-8
A novel evaluation benchmark for medical LLMs illuminating safety and effectiveness in clinical domainsComparison of liquid biopsy-based technologies for cancer screening
Crit Rev Clin Lab Sci. 2025 Dec 27:1-12. doi: 10.1080/10408363.2025.2606357. Online ahead of print.
ABSTRACT
Circulating plasma DNA has found important applications in diverse medical fields, including prenatal testing, transplantation, and especially cancer. Many companies have developed products for detecting minimal residual disease, selecting or monitoring therapy, assessing prognosis, and confirming diagnosis. One major application is in screening asymptomatic individuals for the presence of cancer. Screening may facilitate better clinical outcomes through earlier interventions. Collectively, these technologies are widely known as "liquid biopsies". After the extraction of free DNA from the circulation, it is analyzed by various molecular techniques to explore differences between DNA originating from normal cells and cancer cells. Circulating plasma DNA originating from tumors (ctDNA) is expected to harbor the same molecular changes as tumor tissue itself. Thus, ctDNA is considered a surrogate of cancer tissue, but without the need to perform invasive biopsies to obtain it. Many new diagnostic companies have taken advantage of this new biomarker and developed technologies for screening for one or multiple cancers. We previously estimated the amount of ctDNA in circulation, which is admixed with DNA originating from normal cells. We concluded that since only a small fraction of the whole plasma (3 liters) is used for testing (3 to 4 mL), it is possible that the retrieved ctDNA may not be enough for cancer diagnosis in all patients. This problem is more acute with small tumors. Here, we mention some companies in the "liquid biopsy" arena and analyze their clinical data to establish if their tests are close to entering the clinic. We conclude from this analysis that current data do not support the use of these technologies for population screening due to many false negative and false positive results.
PMID:41454842 | DOI:10.1080/10408363.2025.2606357